UBS lowers Vtex price target to $10 on weak LatAm outlook

UBS lowered its price target on Vtex to $10 from $11, maintaining a Buy rating despite expecting weakness in Latin American markets outside Brazil to impact 2025 net income by nearly 10%. The firm's outlook contrasts with Jefferies, which initiated a Hold rating citing decelerating growth and high costs, and BofA Securities, which raised its price target to $10 with a Buy rating, highlighting potential in the U.S. and Europe. Despite the price target cut, UBS maintains a positive outlook on Vtex, stating that "the thesis remains solid" for the company.

Analysis

Vtex (VTEX), currently trading at $6.55 after a 12.9% year-to-date gain, faces a mixed analyst outlook. UBS has lowered its price target to $10.00 from $11.00, maintaining a Buy rating, but revised its 2025 net income forecast downwards by nearly 10% due to expected weakness in Latin American markets outside Brazil; growth in other regions is not yet seen as compensatory. This outlook adjustment occurs despite Vtex's strong gross profit margins of 74.7%, which suggest solid operational efficiency. Jefferies initiated coverage with a Hold rating and a $7.30 price target, citing decelerating growth and high equity costs as potential challenges. Conversely, BofA Securities raised its price target to $10.00 from $9.50, also maintaining a Buy rating, highlighting Vtex's strong performance and growth potential, especially in U.S. and European markets, along with margin expansion capabilities. The stock trades below the broader analyst target range of $7.30 to $12.00, reflecting these divergent views on its operational and financial prospects.

Key Decisions for Investors

• Investors should closely monitor Vtex's upcoming financial reports for tangible progress in U.S. and European market penetration, which is crucial to offset the forecasted weakness in certain Latin American segments and validate the bullish theses presented by UBS and BofA Securities.
• Given the current share price of $6.55 is below all recently cited analyst price targets ($7.30, $10.00), assess individual risk appetite considering the conflicting analyst views – weighing the Buy ratings against Jefferies' concerns about decelerating growth and high equity costs.
• Focus on Vtex's ability to translate its impressive 74.7% gross profit margin into sustainable net income growth, especially in light of UBS's revised, lower 2025 net income expectations.